| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
ESBLPseudomonas aeruginosaAntibiotics (Resistance)CarbapenemaseUrinary tract infection| 1 | 2003 | Recent developments in beta lactamases and extended spectrum beta lactamases. | 
| + | - | nl | BMJ 327(7425):1209-13 (2003) |
| 2 | 2004 | Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. |
| + | - | nl | Antimicrob Agents Chemother 48(12):4574-81 (2004) |
| 3 | 2004 | Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. |
| + | - | nl | Antimicrob Agents Chemother 48(1):1-14 (2004) |
| 4 | 2003 | Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. |
| + | - | nl | Antimicrob Agents Chemother 47(8):2385-92 (2003) |
| 5 | 1995 | Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure. |
| + | - | nl | Antimicrob Agents Chemother 39(12):2593-601 (1995) |
| 6 | 1991 | More extended-spectrum beta-lactamases. |
| + | - | nl | Antimicrob Agents Chemother 35(9):1697-704 (1991) |
| 7 | 1989 | Extended-spectrum beta-lactamases. |
| + | - | nl | Antimicrob Agents Chemother 33(8):1131-6 (1989) |
| 8 | 2007 | Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. |
| + | - | nl | J Antimicrob Chemother 60(5):913-20 (2007) |
| 9 | 2007 | CTX-M: changing the face of ESBLs in Europe. |
| + | - | nl | J Antimicrob Chemother 59(2):165-74 (2007) |
| 10 | 2005 | CTX-M: changing the face of ESBLs in the UK. |
| + | - | nl | J Antimicrob Chemother 56(3):451-4 (2005) |
| 11 | 2005 | Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. |
| + | - | nl | J Antimicrob Chemother 56(1):52-9 (2005) |
| 12 | 1998 | Extended-spectrum beta-lactamases: the role of inhibitors in therapy. |
| + | - | nl | J Antimicrob Chemother 42(4):415-7 (1998) |
| 13 | 2005 | Extended-spectrum beta-lactamases: a clinical update. |
| + | - | nl | Clin Microbiol Rev 18(4):657-86 (2005) |
| 14 | 2001 | Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. |
| + | - | nl | Clin Microbiol Rev 14(4):933-51, table of contents (2001) |
| 15 | 2008 | Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. |
| + | - | nl | Clin Microbiol Infect 14 Suppl 1(-):198-202 (2008) |
| 16 | 2008 | Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers. |
| + | - | nl | Clin Microbiol Infect 14 Suppl 1(-):189-93 (2008) |
| 17 | 2008 | Control of infections due to extended-spectrum beta-lactamase-producing organisms in hospitals and the community. |
| + | - | nl | Clin Microbiol Infect 14 Suppl 1(-):124-33 (2008) |
| 18 | 2008 | Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide. |
| + | - | nl | Clin Microbiol Infect 14 Suppl 1(-):90-103 (2008) |
| 19 | 2008 | Extended-spectrum beta-lactamases: structure and kinetic mechanism. |
| + | - | nl | Clin Microbiol Infect 14 Suppl 1(-):63-74 (2008) |
| 20 | 2008 | IRT and CMT beta-lactamases and inhibitor resistance. |
| + | - | nl | Clin Microbiol Infect 14 Suppl 1(-):53-62 (2008) |
| 21 | 2008 | Minor extended-spectrum beta-lactamases. |
| + | - | nl | Clin Microbiol Infect 14 Suppl 1(-):42-52 (2008) |
| 22 | 2008 | The spread of CTX-M-type extended-spectrum beta-lactamases. |
| + | - | nl | Clin Microbiol Infect 14 Suppl 1(-):33-41 (2008) |
| 23 | 2008 | Evolution of extended-spectrum beta-lactamases by mutation. |
| + | - | nl | Clin Microbiol Infect 14 Suppl 1(-):11-32 (2008) |
| 24 | 2008 | Defining an extended-spectrum beta-lactamase. |
| + | - | nl | Clin Microbiol Infect 14 Suppl 1(-):3-10 (2008) |
| 25 | 2005 | Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. |
| + | - | nl | Clin Microbiol Infect 11 Suppl 6(-):10-7 (2005) |
| 26 | 2005 | Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs). |
| + | - | nl | Clin Microbiol Infect 11 Suppl 4(-):1-16 (2005) |
| 27 | 2001 | Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms. |
| + | - | nl | Clin Microbiol Infect 7(11):597-608 (2001) |
| 28 | 2005 | Extended-spectrum beta-lactamases: the end of cephalosporins? |
| + | - | nl | Isr Med Assoc J 7(5):336-8 (2005) Colodner R |
| 29 | 2011 | Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. |
| + | - | nl | Mayo Clin Proc 86(3):250-9 (2011) |
| 30 | 2006 | Extended-spectrum beta-lactamases and clinical outcomes: current data. |
| + | - | nl | Clin Infect Dis 42 Suppl 4(-):S164-72 (2006) |
| 31 | 2006 | Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases. |
| + | - | nl | Clin Infect Dis 42 Suppl 4(-):S153-63 (2006) |
| 32 | 2009 | Human health hazards from antimicrobial-resistant Escherichia coli of animal origin. |
| + | - | nl | Clin Infect Dis 48(7):916-21 (2009) |
| 33 | 2008 | ESBLs detection in clinical microbiology: why & how? | 
| + | - | nl | Indian J Med Res 127(4):297-300 (2008) |
| 34 | 2010 | Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. |
| + | - | nl | J Antimicrob Chemother 65 Suppl 3(-):iii25-33 (2010) |
